EB Pharma Developments SRL
The score of EB Pharma Developments shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -70 % Total assets -23 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →EB Pharma Developments's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Mar 2026
- Year ended 31 Dec 2024filed on 25 Jul 2025
- Year ended 31 Dec 2023filed on 30 Jul 2024
- Year ended 31 Dec 2022filed on 22 Aug 2023
EB Pharma Developments's financial analysis
- Solvency31.3%sector median: 57.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of EB Pharma Developments
EB Pharma Developments's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0780.755.671
- VAT number
- BE0780755671
- Peppol
- Registered · 0208:0780755671 · as of 18 Oct 2026
- Legal form
- SRL
- Incorporated
- 21 Jan 2022
- Registered office
- 3570 Alken
- Latest accounts
- 2025 · filed on 25 Mar 2026
- Activity
- Other liberal professions and professional, scientific and technical activities n.e.c. (NACE 74999)
EB Pharma Developments (SRL) has been based in Alken since 2022, active in: other liberal professions and professional, scientific and technical activities n.e.c.. For 2025, it reports a net loss of 1,347 € and equity of 5,298 €; its revenue is not published. Its solvency stands at 31.3%, below the median of its sector (57.4%).
Companies similar to EB Pharma Developments
Companies in the same business, of comparable size and area, outside its group.
- VKJ-Engineering Research and experimental development on natural sciences and engineering Heist-op-den-Berg · balance sheet 41,764 €
- Hygie Quality Services All other professional, scientific and technical activities n.e.c. Chaudfontaine · balance sheet 99,081 €
- Cmax Biotech Consulting Research and experimental development on natural sciences and engineering Hasselt · balance sheet 52,078 €
- D.C.V.E. Solutions All other professional, scientific and technical activities n.e.c. Kortenaken · balance sheet 97,996 €
- Care&D Research and experimental development on natural sciences and engineering Bertrix · balance sheet 112,187 €
- eScienceQPS All other professional, scientific and technical activities n.e.c. Westerlo · balance sheet 231,873 €
- Emelie Flemming-Parker Research and experimental development on natural sciences and engineering Tongeren-Borgloon · balance sheet 114,901 €
- Vision3F Research and experimental development on natural sciences and engineering Rotselaar · balance sheet 483,697 €
Frequently asked questions about EB Pharma Developments
What is the revenue of EB Pharma Developments?
EB Pharma Developments files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of EB Pharma Developments?
In Belgium, the VAT number is the company number prefixed with BE: BE0780755671 for EB Pharma Developments, if the company is VAT-registered. Its company number (CBE) is 0780.755.671.
Where is the registered office of EB Pharma Developments?
According to the CBE register, the registered office of EB Pharma Developments is in 3570 Alken.
What is the equity of EB Pharma Developments?
At the close of the 2025 financial year, the equity of EB Pharma Developments amounts to 5,298 €, a solvency of 31.3% of total assets.
Who manages EB Pharma Developments?
The register lists 1 active mandates at EB Pharma Developments. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of EB Pharma Developments
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →